Our results reveal that EBV LMP-1-mediated over-expression of SATB1 is associated with NPC progression, suggesting SATB1 may represent a promising biomarker and therapeutic target for NPC. This evidence concerns the gene PDLIM7 and nasopharyngeal carcinoma.